CN110446492A - 用于减少体重及减少体脂肪的组合物及其医药品与应用 - Google Patents

用于减少体重及减少体脂肪的组合物及其医药品与应用 Download PDF

Info

Publication number
CN110446492A
CN110446492A CN201880017748.9A CN201880017748A CN110446492A CN 110446492 A CN110446492 A CN 110446492A CN 201880017748 A CN201880017748 A CN 201880017748A CN 110446492 A CN110446492 A CN 110446492A
Authority
CN
China
Prior art keywords
weight
stearate
polyoxyethylene
composition
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880017748.9A
Other languages
English (en)
Inventor
凌玉芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caliway Biopharmaceuticals Co Ltd
Original Assignee
Caliway Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caliway Biopharmaceuticals Co Ltd filed Critical Caliway Biopharmaceuticals Co Ltd
Publication of CN110446492A publication Critical patent/CN110446492A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

本发明公开一种用于减少体重及减少体脂肪的组合物及其医药品与应用，该组合物包含表没食子儿茶素没食子酸酯、姜黄素、以及一赋形剂，该赋形剂为甘油二山俞酸酯、聚氧乙烯硬脂酸酯、聚山梨醇酯80混合物、维生素E聚乙二醇琥珀酸酯、单硬脂酸甘油酯、以及油酸聚乙二醇‑6甘油酯中的至少一种或其组合；而且，该聚山梨醇酯80混合物包含聚山梨醇酯80以及偏硅酸镁铝。本发明所述的组合物在先诱导肥胖模式的动物试验或同时诱导肥胖的动物试验中，皆具有显著减少体重与体脂肪的效果。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN201880017748.9A 2017-03-28 2018-03-28 用于减少体重及减少体脂肪的组合物及其医药品与应用 Pending CN110446492A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477514P 2017-03-28 2017-03-28
US62/477,514 2017-03-28
PCT/CN2018/080968 WO2018177340A1 (zh) 2017-03-28 2018-03-28 用于减少体重及减少体脂肪的组合物及其医药品与应用

Publications (1)

Publication Number Publication Date
CN110446492A true CN110446492A (zh) 2019-11-12

Family

ID=63675259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880017748.9A Pending CN110446492A (zh) 2017-03-28 2018-03-28 用于减少体重及减少体脂肪的组合物及其医药品与应用

Country Status (8)

Country Link
EP (1) EP3603628A4 (zh)
JP (1) JP2020515552A (zh)
KR (1) KR20190134671A (zh)
CN (1) CN110446492A (zh)
AU (2) AU2018241639B2 (zh)
CA (1) CA3055451C (zh)
TW (1) TWI676476B (zh)
WO (1) WO2018177340A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498616A (zh) * 2018-12-29 2019-03-22 中国医科大学附属第医院 Egcg在制备改善肝脏炎症及胰岛素抵抗药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274343A1 (en) * 2011-05-16 2013-10-17 Omniactive Health Technologies Ltd Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof
CN103717224A (zh) * 2011-06-07 2014-04-09 独立行政法人科学技术振兴机构 一氧化碳(co)对脂肪酸和胆固醇摄取的抑制
US20150182625A1 (en) * 2012-08-04 2015-07-02 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2016029868A1 (zh) * 2014-08-28 2016-03-03 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
WO2017037594A2 (zh) * 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4012894B2 (ja) * 2003-09-17 2007-11-21 レキオファーマ株式会社 ウコン含有組成物
CN103784421B (zh) * 2014-02-27 2016-04-27 哈尔滨医科大学 载姜黄素和胡椒碱的固体脂质纳米粒及其制备方法
US10940125B2 (en) * 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274343A1 (en) * 2011-05-16 2013-10-17 Omniactive Health Technologies Ltd Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof
CN103717224A (zh) * 2011-06-07 2014-04-09 独立行政法人科学技术振兴机构 一氧化碳(co)对脂肪酸和胆固醇摄取的抑制
US20150182625A1 (en) * 2012-08-04 2015-07-02 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2016029868A1 (zh) * 2014-08-28 2016-03-03 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
WO2017037594A2 (zh) * 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIN-HSIUNG PAN: "Chemoprevention of nonalcoholic fatty liver diseaseby dietary natural compound", 《MOLECULAR NUTRITION FOOD RESEARCH》 *
TAKUJI SUZUKI: "Beneficial Effects of Tea and the Green Tea Catechin Epigallocatechin-3-gallate on Obesity", 《MOLECULES》 *

Also Published As

Publication number Publication date
EP3603628A4 (en) 2020-12-02
TW201836602A (zh) 2018-10-16
TWI676476B (zh) 2019-11-11
AU2018241639B2 (en) 2020-10-15
EP3603628A1 (en) 2020-02-05
AU2020277116A1 (en) 2020-12-24
KR20190134671A (ko) 2019-12-04
WO2018177340A1 (zh) 2018-10-04
CA3055451C (en) 2021-10-12
AU2018241639A1 (en) 2019-11-14
JP2020515552A (ja) 2020-05-28
CA3055451A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
TWI580427B (zh) Compositions for reducing body weight and reducing body fat, and pharmaceuticals and applications thereof
RU2586300C1 (ru) Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты
CN102205011A (zh) 一种具有减肥功能的药物组合物
CN104320981A (zh) 葎草提取物在预防或治疗代谢紊乱或脂肪肝中的用途
US20200230102A1 (en) Composition and medical product for reducing body weight and body fat, and use of said product
CN103479635A (zh) 一种用于预防和治疗非酒精性脂肪肝的药物组合物及其用途
CN110446492A (zh) 用于减少体重及减少体脂肪的组合物及其医药品与应用
WO2015188428A1 (zh) 一种应用于治疗代谢综合征的药物
JP2010168399A (ja) 血糖の上昇を抑制するための薬剤
JPWO2005082391A1 (ja) ヒトβ３アドレナリン受容体アゴニスト剤
RU2780451C1 (ru) Композиция на основе лекарственных материалов традиционной китайской медицины для лечения метаболического синдрома, способ ее получения и применение, и фармацевтический препарат на ее основе и его применение
KR20170026241A (ko) 경구용 복합제제
KR20170026242A (ko) 간 질환의 예방 또는 치료용 약학적 조성물
CN100358553C (zh) 一种具有降脂减肥作用的中药组合物及制备方法
JP4465963B2 (ja) 高脂血症の予防または改善用組成物
CN106563038B (zh) 一种牛磺酸和脂溶性茶多酚复方组合物及其制备方法与应用
CN104523662B (zh) 一种治疗非酒精性脂肪肝的药物组合物及其应用
WO2015192445A1 (zh) 赶黄草或其提取物在制备预防或治疗非酒精性脂肪肝的保健品或药物中的用途
CN116570601A (zh) 一种治疗非酒精性脂肪肝的药物组合物
EP4274566A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
KR101346879B1 (ko) 하이드록시비페닐 유도체를 유효성분으로 함유하는 비만, 당뇨, 지방간, 또는 고지혈증 치료 및 예방용 조성물 및 건강기능식품
CN113440517A (zh) 利卡灵b在制备预防或/和治疗非酒精性脂肪肝病药物中的应用
CN116747228A (zh) 异莲心碱在制备抗脂肪性肝病产品中的应用
CN103768048B (zh) 水飞蓟宾葡甲胺片及其降脂作用
CN114177185A (zh) 一种用于降低胆固醇与预防心血管疾病的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011083

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191112